TLR7 and melanoma: In support of an immunogenic pDC role, imiquimod (TLR7 agonist)-mediated regression of melanoma tumors was shown to be dependent on TLR7 expression on pDCs; neither mice lacking TLR7 nor pDC-depleted mice responded to imiquimod therapy and both saw a reduction in apoptosis within treated tumors (78).